Last Updated : May 13, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Ferriprox | Deferiprone | Transfusional iron overload | List with clinical criteria and/or conditions | Complete | ||
| Ferriprox | deferiprone | Transfusional iron overload | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ferinject | ferric carboxymaltose | Iron deficiency anemia | Received | |||
| Ferinject | ferric carboxymaltose | Iron deficiency in adult patients with heart failure | Received | |||
| Fentora | Fentanyl buccal | Pain (breakthrough), cancer (adults) | Do not reimburse | Complete | ||
| Faslodex | Fulvestrant | Locally advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Fasenra | benralizumab | Asthma, severe eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Fasenra | benralizumab | Asthma, severe eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Fampyra | Fampridine | Multiple sclerosis, improve walking disability | Withdrawn | |||
| Fampyra | Fampridine | Multiple sclerosis, improve walking disability | Do not list | Complete |
Last Updated : May 13, 2024